目的：探讨尼可地尔治疗三支血管病变冠心病患者的临床效果。方法随机选取2011年7月至2014年7月我院收治的冠心病三支血管病变患者84例，随机数表法分组，其中42例常规治疗者为对照组，42例加用尼可地尔治疗者为观察组。疗程为3个月，3个月后观察两组患者每日心绞痛发作次数及持续时间、硝酸甘油服用量、心梗等心脑血管事件发生情况，并根据SF-36量表对患者生活质量进行评估。结果治疗3个月后，两组患者的每日心绞痛发作次数、持续时间、硝酸甘油服用量均有所减少，且观察组明显优于对照组，各指标比较差异均具有统计学意义(P<0.05)；治疗期间两组并发症均较少，观察组和对照组发生率分别为4.8%和10.4%，差异具有统计学意义(P<0.05)；治疗后两组生活质量均有所改善，且观察组明显优于对照组，其差异具有统计学意义(P<0.05)。结论尼可地尔治疗冠心病三支病变者的临床效果较好，可明显改善心绞痛症状，提高患者生活质量，且并发症较少。%Objective To explore the clinical value of Nicorandil in patients with triple-vessel coronary heart disease. Methods Eighty-four patients with triple-vessel coronary heart disease in our hospital from July 2011 to July 2014 were divided into two groups by random number table. The 42 patients in control group received conven-tional treatment, while the 42 patients in the observation group added Nicorandil for treatment based on the control group. All the patients were treated for 3 months. Then the daily frequency and duration of angina pectoris, nitroglycer-in dose, myocardial infarction and other cardiovascular and cerebrovascular events were observed. The quality of life of patients was assessed according to SF-36 questionnaire. Results After treatment, the daily frequency and duration of angina pectoris, nitroglycerin dose in the two groups were all declined, and the improvement was significantly better in the observation group than the control group, with statistically significant difference between the two groups (P<0.05). The incidence of complications of both groups were low, with 4.8%in the observation group and 10.4%in the control group, showing statistically significant difference between the two groups (P<0.05). Quality of life scores after treat-ment were improved in both group, and the improvement in the observation group was significantly better (P<0.05). Conclusion Nicorandil has great effect on triple-vessel coronary heart disease. It can improve the angina symptoms sig-nificantly and improve the quality of life of patients, and results in less complications, which is worthy of promotion.
展开▼
